重组人血管内皮抑制素联合腔内化疗治疗恶性胸腔积液疗效观察  

Clinical observation of the efficacy of intracavitary injection of endostar combined with chemotherapy on ma-lignant pleural effusion

作　　者：张文兵 谢同芳 

机构地区：[1]淮南东方医院集团肿瘤医院肿瘤科,安徽省淮南232035

出　　处：《中国基层医药》2015年第8期1212-1214,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的：观察重组人血管内皮抑制素（恩度）联合腔内化疗治疗恶性胸腔积液的疗效和安全性。方法46例恶性胸腔积液患者非随机分为腔内恩度联合化疗组（治疗组）和腔内化疗组（对照组）。治疗前均先排尽胸水，治疗组在胸腔内注入顺铂（DDP）60 mg和恩度45 mg。对照组除不加入恩度外，其余同治疗组，每周2次，共2～4次，观察两组疗效和安全性。结果治疗组有效率为58．3％，对照组有效率为31．8％，两组差异有统计学意义（χ^2＝4．547，P＜0．05）；治疗组生活质量改善率为75．0％，对照组为59．1％，两组差异有统计学意义（χ^2＝5．371，P＜0．05）；治疗组毒性反应与对照组相近，未明显增加。结论腔内恩度联合化疗治疗恶性胸腔积液安全有效。Objective To study the efficacy and safety of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion.Methods 46 cases with malignant pleural effusion were divided into groups of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion （treatment group）and groups of intracavitary chemotherpy（control group）randomly,pleural effusion of the patients from the two groups were injected cisplatin（DDP）60mg into the thorax and 45mg of endostar,The same therapy applied to the control group except adding endostar,twice a week,in 2 -4 rounds,the efficacy and safety of the two groups were studied.Results The effective rate of the treatment groups was 58.3%,which was higher than 31.8%of the control group （χ^2 =4.547,P〈0.05）.The improvement rate of quality of life was 75.0% in the treatment group,which was higher than 59.1% in the control group （χ^2 =5.371,P〈0.05）.The toxicities of the treatment group were not increased significantly.Conclusion The therapy of intracavitary injection of endostar combined with chemotherapy of malignant pleural effusion is effective and secure.

关 键 词：重组人血管内皮抑制素 恶性胸腔积液 腔内化疗 

分 类 号：R730.5[医药卫生—肿瘤]